IPCALAB IPCA Laboratories Q3 FY25 results (Oct–Dec 2024) and concall
Ipca Labs reported a strong Q3 FY25 with significant margin expansion across both standalone and consolidated entities, driven by improved product mix, operational efficiencies, and Unichem's turnaround. Domestic formulation and API businesses showed robust growth. However, the generics segment faced headwinds in South Africa and the institutional antimalarial business is under pressure due to US aid cuts, while new capacities await regulatory clearances.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 2,355 | 2,245 |
| EBITDA | 441 | 463 |
| Net profit | 246 | 276 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
